Filing Flows › Journey Medical (DERM) › Accutane revenue
Journey Medical (DERM) Accutane revenue by quarter
Journey Medical's Accutane revenue was $3.4M in Q2 2026 (second quarter 2026), +1% from Q1 2026. Over the last 7 quarters it ranged from $2.8M (Q3 2025) to $3.9M (Q4 2024).
| Quarter | Accutane revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $3.4M | +1% | -1% |
| Q1 2026 | $3.3M | +8% | -9% |
| Q4 2025 | $3.1M | +11% | -21% |
| Q3 2025 | $2.8M | -18% | — |
| Q2 2025 | $3.4M | -7% | — |
| Q1 2025 | $3.7M | -6% | — |
| Q4 2024 | $3.9M | — | — |
Q2 2026 at a glance
Journey Medical, Q2 2026: revenue $18.5M (+23% year over year), operating margin 2.5%, net loss $312K, operating cash flow −$1.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Journey Medical's Accutane revenue?
Journey Medical's Accutane revenue was $3.4M in Q2 2026 (second quarter 2026), +1% from Q1 2026.
How has Journey Medical's Accutane revenue changed?
Over the last 7 quarters it ranged from $2.8M (Q3 2025) to $3.9M (Q4 2024).